Balaji Amines (530999) Aktienübersicht
Balaji Amines Limited beschäftigt sich mit der Herstellung und dem Verkauf von Methylaminen, Ethylaminen und Derivaten von Spezialchemikalien und pharmazeutischen Hilfsstoffen in Indien. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 4/6 |
Belohnungen
Risikoanalyse
530999 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Balaji Amines Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹2,107.20 |
| 52-Wochen-Hoch | ₹2,260.00 |
| 52-Wochen-Tief | ₹905.15 |
| Beta | 0.79 |
| 1 Monat Veränderung | 23.91% |
| 3 Monate Veränderung | 110.80% |
| 1 Jahr Veränderung | 45.87% |
| 3 Jahre Veränderung | -11.08% |
| 5 Jahre Veränderung | -16.63% |
| Veränderung seit IPO | 16,710.53% |
Aktuelle Nachrichten und Updates
Recent updates
530999: Lower Multiple Expectations Will Drive Cautious View Despite Margin Optimism
Analysts have trimmed their fair value estimate for Balaji Amines from ₹1,561 to ₹1,334, citing updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for May 13, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments) Board to consider recommending a final dividend on equity shares for the financial year ended March 31, 2026, subject to shareholder approval at the 38th Annual General Meeting (Key Developments) Matters related to the upcoming 38th Annual General Meeting, including formal approvals and shareholder items, are also on the board meeting agenda (Key Developments) Valuation Changes Fair Value: Trimmed from ₹1,561 to ₹1,334, indicating a lower central estimate for the stock's worth based on updated assumptions.
530999: Higher Assumed Margins And P E Multiple Will Likely Limit Upside
Analysts have maintained their price target for Balaji Amines at ₹1,334. This reflects updated views based on a slightly lower discount rate, a modestly higher assumed revenue growth of 21.69% and a profit margin of 14.49%, as well as a revised future P/E assumption of 18.64x.
530999: Higher Revenue Outlook And Lean Margins Will Support Future Upside
Analysts have trimmed their price target for Balaji Amines from ₹1,616.67 to ₹1,447.50, reflecting updated assumptions around discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair Value: Trimmed from ₹1,616.67 to ₹1,447.50, indicating a lower central estimate for the share price.530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have kept the price target for Balaji Amines steady at ₹1,561, citing slightly adjusted assumptions on the discount rate, revenue growth, profit margin and forward P/E as the main factors behind the unchanged view. What's in the News A board meeting is scheduled for January 29, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have maintained their fair value estimate for Balaji Amines at ₹1,334. The steady price target is supported by only small adjustments to the discount rate, revenue growth assumptions, profit margin and future P/E expectations.530999: Refined Margins And P E Assumptions Will Likely Support Returns
Analysts have kept their fair value estimate for Balaji Amines steady at ₹1,334, with small refinements to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this unchanged price target. What's in the News A board meeting is scheduled on Jan 29, 2026 to consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).530999: Higher Future P E And Margins Will Likely Support Returns
Analysts have maintained their price target for Balaji Amines at ₹1,334, reflecting a balance between a lower discount rate, slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a marginally higher future P/E multiple. What's in the News Board meeting scheduled for January 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025.530999: Higher Margin Outlook And Upcoming Results Will Support Bullish Repricing
Analysts have revised their price target for Balaji Amines from ₹2,331 to ₹1,561, reflecting updated views on a lower assumed revenue growth rate, a slightly higher discount rate, a higher profit margin, and a reduced future P/E multiple. What's in the News Board meeting scheduled for Jan 29, 2026, to review and approve the unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).530999: Richer Forward P/E Will Likely Support Returns Despite Thinner Margins
Analysts have raised their price target for Balaji Amines from ₹1,185 to ₹1,334, reflecting revised assumptions of higher revenue growth and a richer forward P/E multiple, partly offset by a lower profit margin outlook and a slightly higher discount rate. What's in the News Board meeting scheduled on Jan 29, 2026, to consider, approve and take on record the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).530999: Stable Margins And Upcoming Results Will Support Further Upside
Analysts have maintained their price target for Balaji Amines at ₹1,616.67, reflecting largely unchanged assumptions on the discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for November 10, 2025, to consider and approve the unaudited standalone financial results for the quarter and half year ended September 30, 2025 (company filing).530999 Will Likely See Slower Expansion Offset By Stronger Profit Margins
Analysts have reduced their fair value estimate for Balaji Amines to ₹1,185 from ₹1,598, citing expectations of slower revenue growth and a lower future P E multiple. This is partially offset by improved projected profit margins and a slightly higher discount rate.530999: Stable Margins And Growth Outlook Will Support Further Upside
Analysts have modestly lifted their price target on Balaji Amines to ₹1,616.67 per share, reflecting slightly higher assumed discount rates and steady long term growth and margin expectations that together support a marginally richer valuation multiple. What's in the News Board meeting scheduled on November 10, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).530999: Rising Profit Margins Will Drive Further Upside Despite Slower Sales
Analysts have revised their price target for Balaji Amines downward from ₹1,847 to ₹1,617. This change is due to expectations of slower revenue growth, even though profit margin projections have improved.New Plant Launches And Certifications Set To Drive Future Operational Efficiency And Revenue Potential
With both the Future P/E and Discount Rate showing only marginal changes, analysts have effectively maintained their valuation outlook for Balaji Amines, resulting in an unchanged consensus price target of ₹1847. What's in the News Board meeting scheduled to consider and approve un-audited standalone and consolidated financial results for the quarter ended 30 June 2025.
New Plant Launches And Certifications Set To Drive Future Operational Efficiency And Revenue Potential
New plant expansions and strategic focus on high-margin products promise revenue growth and improved net margins through enhanced efficiency and diversification.Aktionärsrenditen
| 530999 | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 0.6% | 3.2% | 2.8% |
| 1Y | 45.9% | -3.5% | -1.5% |
Rendite im Vergleich zur Industrie: 530999 übertraf die Branche Indian Chemicals , die im vergangenen Jahr eine Rendite von -3.5 erzielte.
Rendite vs. Markt: 530999 übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von -1.5 erzielte.
Preisvolatilität
| 530999 volatility | |
|---|---|
| 530999 Average Weekly Movement | 10.4% |
| Chemicals Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stabiler Aktienkurs: Der Aktienkurs von 530999 war in den letzten 3 Monaten im Vergleich zum Indian -Markt volatil.
Volatilität im Zeitverlauf: 530999Die wöchentliche Volatilität (10%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Indian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1988 | 1,169 | Dundurapu Reddy | www.balajiamines.com |
Balaji Amines Limited beschäftigt sich mit der Herstellung und dem Verkauf von Methylaminen, Ethylaminen und Derivaten von Spezialchemikalien und pharmazeutischen Hilfsstoffen in Indien. Das Unternehmen ist in zwei Segmenten tätig: Chemie und Hotel. Es bietet Monomethylamin, Dimethylamin, Trimethylamin, Monoethylamin, Diethylamin, Triethylamin sowie Dimethyl- und Diethylaminoethanol und Spezialchemikalien, darunter N-Methylpyrrolidon, Morpholin, 2-Pyrrolidon, N-Ethyl-2-Pyrrolidon, Gamma-Butyrolacton, Dimethylformamid, Acetonitril, Dimethylcarbonat, Propylenglykol und Propylencarbonat.
Balaji Amines Limited's Grundlagenzusammenfassung
| 530999 grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹68.28b |
| Gewinn(TTM) | ₹1.67b |
| Umsatz(TTM) | ₹14.25b |
Ist 530999 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 530999 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹14.25b |
| Kosten der Einnahmen | ₹7.96b |
| Bruttogewinn | ₹6.29b |
| Sonstige Ausgaben | ₹4.62b |
| Gewinn | ₹1.67b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 51.60 |
| Bruttomarge | 44.14% |
| Nettogewinnspanne | 11.73% |
| Schulden/Eigenkapital-Verhältnis | 6.2% |
Wie hat sich 530999 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt 530999 eine zuverlässige Dividende?
Siehe 530999 Dividendenhistorie und Benchmarks| Balaji Amines Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jul 03 2026 |
| Datum der Dividendenzahlung | Aug 09 2026 |
| Tage bis Ex-Dividende | 17 days |
| Tage bis zum Datum der Dividendenzahlung | 54 days |
Zahlt 530999 eine zuverlässige Dividende?
Siehe 530999 Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/15 05:46 |
| Aktienkurs zum Tagesende | 2026/06/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Balaji Amines Limited wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Nilesh Ghuge | HDFC Securities Limited |
| Jay Gandhi | HDFC Securities Limited |
| Keshav Lahoti | HDFC Securities Limited |